Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET) is an indication for drug development with over 30 pipeline drugs currently active. According to GlobalData, preregistered drugs for Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET) have a 80% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET) compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET) overview
Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are a rare and heterogeneous group of neoplasms that originate from neuroendocrine cells in the gastrointestinal tract and pancreas. These cells produce hormones that regulate various functions in the body. GEP-NETs can be classified as functional or non-functional, depending on whether they secrete excess hormones or not. Functional GEP-NETs can cause various syndromes, such as carcinoid syndrome, Zollinger-Ellison syndrome, or Verner-Morrison syndrome, depending on the type of hormone produced. Non-functional GEP-NETs may not cause any symptoms until they grow large or metastasize to other organs. The diagnosis of GEP-NETs is based on histopathology, immunohistochemistry, and hormonal assays. The treatment options include surgery, chemotherapy, radiotherapy, somatostatin analogues, peptide receptor radionuclide therapy, and targeted therapy. The prognosis of GEP-NETs depends on several factors, such as the tumor grade, stage, location, and functionality.
See Also:
For a complete picture of PTSR and LoA scores for drugs in Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET), buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
